Dirk Nagorsen

C4 Therapeutics (United States) — United States

Immunology and Microbiology · Life Sciences

40h-index11.2kcitations131works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(62), CAR-T cell therapy research(59), T-cell and B-cell Immunology(32), Cancer Immunotherapy and Biomarkers(31), Immune Cell Function and Interaction(23)

Publications131 total

Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance
Journal for ImmunoTherapy of Cancer·2025· 1 citedOpen Access
A phase I study of AFNT-211, autologous CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors.
Journal of Clinical Oncology·2025· 1 cited
Regional distribution of HLA frequencies in the USA: implications for TCR-based therapies
Journal for ImmunoTherapy of Cancer·2025· 1 citedOpen Access
Abstract CT149: A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor, in patients with advanced or metastatic solid tumors
Cancer Research·2025
Abstract 3745: Allele-specific HLA LOH frequencies and survival outcomes in cancer: a real-world analysis
Cancer Research·2025
662 A phase1 study of autologous engineered CD4+ and CD8+ T cells, HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor and a FAS41BB switch receptor in patients with solid tumors
Regular and Young Investigator Award Abstracts·2024Open Access
Integrating US census demographic data with HLA frequencies to accelerate targeted cell therapy patient enrollment
Human Immunology·2024
Correlation of allele-specific HLA loss of heterozygosity in patients with cancer with driver mutations.
Journal of Clinical Oncology·2024
AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors.
Journal of Clinical Oncology·2024· 5 cited
Abstract CT076: AFNT-211: A phase1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor; and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
Cancer Research·2024· 2 cited
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics
Nature Reviews Drug Discovery·2023· 5 cited
AFNT-211: An FAS-41BB–enhanced TCR-T cell therapy with stem-like properties targeting KRAS G12V-expressing solid tumors.
Journal of Clinical Oncology·2023· 2 cited
Supplementary Material from First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Data from First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Data from First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Material from First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
Journal of Clinical Oncology·2023· 251 citedOpen Access
Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy
Annual Review of Cancer Biology·2021· 72 citedOpen Access
Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy
Journal of Clinical Oncology·2021· 88 citedOpen Access
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
Journal for ImmunoTherapy of Cancer·2020· 110 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Ralf C. Bargou(14), Eckhard Thiel(12), Gerhard Zugmaier(11), Carmen Scheibenbogen(11), Ulrich Keilholz(11), Peter Kufer(9), Patrick A. Baeuerle(9), Monika Brüggemann(8), Max S. Topp(8), Anne Letsch(8), Francesco M. Marincola(8), Nicola Gökbuget(7), Matthias Klinger(7), Andreas Viardot(7), Alexander Schmittel(6), Vladia Monsurrò(6), Ena Wang(6), Monica C. Panelli(6), Svenja Neumann(5), Margit Schmidt(5)